IBAT Inhibitors: A Class Story

This keynote presentation explores the clinical advancements of IBAT inhibitors—maralixibat, odevixibat, and linerixibat—targeting genetic cholestasis and primary biliary cholangitis (PBC). It delves into cholestatic liver disease pathophysiology, IBAT's mechanism of action, and trial outcomes including ICONIC, PEDFIC, and GLISTEN. Comparative efficacy, safety profiles, and regulatory approvals are reviewed, highlighting transformative impacts on pruritus, quality of life, and bile acid...